“Neuropathic Pain Market Size And Forecast by 2031
According to Data Bridge Market Research Data Bridge Market Research analyses that the global neuropathic pain market, which was USD 5.86 billion in 2023, is expected to reach USD 11.86 billion by 2031, and is expected to undergo a CAGR of 9.2% during the forecast period of 2024 to 2031.
Our comprehensive Neuropathic Pain Market report is ready with the latest trends, growth opportunities, and strategic analysis. https://www.databridgemarketresearch.com/reports/global-neuropathic-pain-market
Segments
- By Drug Class: Anticonvulsants, Antidepressants, Topical Treatments, NSAIDs
- By indication: Diabetic Neuropathy, Postherpetic Neuralgia, Chemotherapy-Induced Peripheral Neuropathy, Trigeminal Neuralgia, Others
- By distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By end user: Hospitals, Specialty Clinics, Home Healthcare, Others
Neuropathic pain is a complex chronic pain condition that is caused by damage or dysfunction to the nervous system. The market for neuropathic pain is segmented based on drug class, indication, distribution channel, and end user. In terms of drug class, the market is categorized into anticonvulsants, antidepressants, topical treatments, and NSAIDs. Anticonvulsants and antidepressants are the most commonly prescribed medications for neuropathic pain management due to their mechanism of action in modulating pain signals in the brain. Topical treatments are also gaining traction in the market for their localized pain relief benefits. The market is further segmented by indication, including diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, and others. Diabetic neuropathy holds a significant share in the market due to the rising prevalence of diabetes globally. Chemotherapy-induced peripheral neuropathy is also a key segment, driven by the increasing cancer incidence and the associated nerve damage from chemotherapy treatment. Distribution channels for neuropathic pain treatment include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are the primary distribution channel due to the availability of a wide range of medications, particularly for severe cases of neuropathic pain. Retail pharmacies and online pharmacies are also witnessing growth, offering convenience and accessibility to patients for prescription refills and over-the-counter medications. End users of neuropathic pain treatment include hospitals, specialty clinics, home healthcare, and others. Hospitals remain the primary end user due to the specialized care and treatment options available for neuropathic pain management, followed by specialty clinics that focus on pain management therapies and rehabilitation services. Home healthcare services are gaining popularity for their cost-effective and personalized care options for patients with chronic pain conditions.
Market Players
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Purdue Pharma L.P.
- GlaxoSmithKline plc
- Eli Lilly and Company
- Abbott
- Biogen
- Astellas Pharma Inc.
- Mylan N.V.
Key market players in the neuropathic pain market include Pfizer Inc., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Purdue Pharma L.P., GlaxoSmithKline plc, Eli Lilly and Company, Abbott, Biogen, Astellas Pharma Inc., and Mylan N.V. These companies have a strong presence in the market with a wide portfolio of neuropathic pain medications and ongoing research and development efforts to introduce innovative treatment options. Strategic collaborations, mergers and acquisitions, and product launches are key strategies adopted by market players to expand their market foothold and address the unmet needs of patients with neuropathic pain.
https://www.databridgemarketresearch.com/reports/global-neuropathic-pain-market The global neuropathic pain market is experiencing significant growth driven by the rising prevalence of chronic pain conditions, increasing awareness about pain management therapies, and advancements in drug development. One of the key trends shaping the market is the shift towards personalized medicine, where healthcare providers are focusing on individualized treatment approaches based on patient’s specific neuropathic pain symptoms and underlying conditions. This trend is driving the demand for innovative therapies with improved efficacy and safety profiles to address the complex nature of neuropathic pain.
Moreover, the market is witnessing a surge in research and development activities aimed at exploring novel drug targets and treatment modalities for neuropathic pain. Biopharmaceutical companies are investing heavily in clinical trials to evaluate the effectiveness of new drug candidates in targeting specific pathways involved in pain perception and transmission. Additionally, the integration of digital health technologies such as telemedicine and wearable devices is enhancing patient monitoring and adherence to treatment regimens, thereby improving overall outcomes for individuals suffering from neuropathic pain.
Furthermore, the market players are focusing on expanding their geographic presence in emerging markets to tap into the growing patient population with unmet medical needs. Collaborations with healthcare providers, regulatory bodies, and patient advocacy groups are facilitating the development and commercialization of innovative therapies for neuropathic pain management. Market players are also emphasizing on patient education initiatives to raise awareness about the importance of timely diagnosis and appropriate management of neuropathic pain to improve patient quality of life.
In conclusion, the global neuropathic pain market is poised for substantial growth in the coming years, driven by advancements in drug development, increasing research and development activities, and a shift towards personalized medicine. Market players need to continue investing in innovative therapies, strategic partnerships, and patient-centric approaches to address the complex needs of individuals suffering from neuropathic pain. As the market evolves, there will be immense opportunities for stakeholders to make a meaningful impact on improving patient outcomes and driving positive changes in the management of neuropathic pain globally.Segments
Global Neuropathic Pain Market, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy, and Proximal Neuropathy), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation, and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, and Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Others), Diagnosis (Imaging, Blood Tests, and Physical Examination) Treatment ( Medications, and Multimodal Therapy) End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization, and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others) – Industry Trends and Forecast to 2031.
In the global neuropathic pain market, various segments play a crucial role in shaping the industry landscape. The type of neuropathic pain treatments available, including spinal cord stimulation devices, external peripheral nerve stimulation, transcutaneous electrical nerve stimulation devices, focal neuropathy, automatic neuropathy, and proximal neuropathy, presents a diverse range of options for patients and healthcare providers. The differentiation between rechargeable and non-rechargeable product types, invasive and non-invasive procedures, as well as technologies like transcutaneous electrical nerve stimulation, transcranial magnetic stimulation, and respiratory electrical stimulation, further highlights the complexity of treatment approaches in neuropathic pain management. Modalities such as stationary and portable devices cater to different patient needs, while the mode of purchase distinguishes between over-the-counter and prescription-based devices. Various pain types and indications, such as spinal stenosis, chemotherapy-induced peripheral neuropathy, and diabetic neuropathy, require tailored treatment strategies based on the specific condition. Diagnosis methods, including imaging, blood tests, and physical examination, are essential for accurate evaluation and personalized treatment plans. Moreover, the end users and distribution channels in the market reflect the diverse healthcare settings where neuropathic pain management occurs, emphasizing the importance of accessibility and efficient delivery of treatments to patients.
Market Players
- NEVRO CORP. (U.S.)
- Lilly (U.S.)
- Astellas Pharma Inc. (Japan)
- Biogen (U.S.)
- Cirtec (U.S.)
- Integer Holdings Corporation (U.S.)
- B. Braun SE (Germany)
- Medtronic (Ireland)
- Abbott (U.S.)
- Boston Scientific Corporation (U.S.)
- OMRON Healthcare Co., Ltd. (Japan)
- electroCore, Inc. (U.S.)
- Polar Medical Ltd (U.K.)
- SunMED Medical (U.S.)
- NeuroMetrix, Inc. (U.S.)
The global neuropathic pain market is characterized by the presence of key market players who contribute significantly to innovations, research, and development in the field of neuropathic pain management. Companies such as NEVRO CORP., Lilly, Astellas Pharma Inc., Biogen, Cirtec, Integer Holdings Corporation, B. Braun SE, Medtronic, Abbott, Boston Scientific Corporation, OMRON Healthcare Co., Ltd., electroCore, Inc., Polar Medical Ltd, SunMED Medical, and NeuroMetrix, Inc. stand out as leaders in the market with their diverse product portfolios catering to various aspects of neuropathic pain treatment. These market players engage in strategic initiatives like partnerships, acquisitions, and product launches to expand their market reach and meet the evolving needs of patients suffering from neuropathic pain. Through continuous research and development efforts, these companies strive to introduce advanced therapies and technologies that enhance patient outcomes and improve the quality of life for individuals with neuropathic pain conditions.
DBMR Cloud-connected intelligence: Bridging the gap with revenue-impacting solutions
DBMR Cloud is a connected intelligence platform that uses a neural network to analyze and integrate macro and micro-level data, bridging the gap between data analytics, market research, and strategy for profound growth and revenue impact.
Get More Detail: https://www.databridgemarketresearch.com/nucleus/global-neuropathic-pain-market
The market is highly fragmented, with a mix of global and regional players competing for market share. To Learn More About the Global Trends Impacting the Future of Top 10 Companies in Neuropathic Pain Market : https://www.databridgemarketresearch.com/reports/global-neuropathic-pain-market/companies
Key Questions Answered by the Global Neuropathic Pain Market Report:
- What is the current state of the Neuropathic Pain Market, and how has it evolved?
- What are the key drivers behind the growth of the Neuropathic Pain Market?
- What challenges and barriers do businesses in the Neuropathic Pain Market face?
- How are technological innovations impacting the Neuropathic Pain Market?
- What emerging trends and opportunities should businesses be aware of in the Neuropathic Pain Market?
Browse More Reports:
https://www.databridgemarketresearch.com/reports/asia-pacific-neuropathic-pain-market
https://www.databridgemarketresearch.com/reports/europe-neuropathic-pain-market
https://www.databridgemarketresearch.com/reports/middle-east-and-africa-neuropathic-pain-market
https://www.databridgemarketresearch.com/reports/north-america-neuropathic-pain-market
https://www.databridgemarketresearch.com/nucleus/asia-pacific-neuropathic-pain-market
https://www.databridgemarketresearch.com/nucleus/europe-neuropathic-pain-market
https://www.databridgemarketresearch.com/nucleus/north-america-neuropathic-pain-market
Data Bridge Market Research:
☎ Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC: +653 1251 982
